| Ytd | -64.69% | |
| 1y | -88.13% |
| Open | 1.15 | Prev Close | 1.13 | Low | 1.10 | High | 1.15 | Mkt Cap | 4.42M |
| Vol | 11.88K | Avg Vol | 43.69K | EPS | -18.45 | P/E | -0.06 | Forward P/E | -0.13 |
| Beta | -0.15 | Short Ratio | 0.11 | Inst. Own | 8.90% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-07 | 50-d Avg | 1.05 | 200-d Avg | 2.06 | 1yr Est | 12.75 |
REVB News
SAN DIEGO, CA / ACCESS Newswire / August 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "
SAN DIEGO, CA / ACCESS Newswire / August 3, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "
SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "C
SAN DIEGO, CA / ACCESS Newswire / July 10, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "C
SAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Co
SAN DIEGO, CA / ACCESS Newswire / May 11, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Co
SAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Com
SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "C
- A majority of CKD patients present with cellular inflammation and immunoparalysis predose - -Gemin
SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "
SAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "
Revelation Biosciences, Inc. (NASDAQ: REVB - Get Free Report) was the target of a large drop in shor
SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (th
SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:RE
SAN DIEGO, CA / ACCESS Newswire / January 23, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the
US stock futures slightly down after 2 days of gains. Trump withdraws tariffs on EU, while Q3 GDP ex
Revelation Biosciences shares jumped after the FDA agreed that a single Phase 2/3 study could suppor
- Single Phase 2/3 Adaptive Study Design - - Clinically Relevant, Objective Composite Endpoint - SAN
- Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study
SAN DIEGO, CA / ACCESS Newswire / January 12, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the
SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the
During Thursday's trading, 110 companies set new 52-week lows.
On Wednesday, 220 stocks hit new 52-week lows.
On Monday, 198 companies hit new 52-week lows.
Thursday's session saw 337 companies set new 52-week lows.
On Friday, 497 companies set new 52-week lows.
Companies Reporting Before The Bell • Zepp Health (NYSE:ZEPP) is expected to report quarterly earni
During Thursday's session, 97 companies made new 52-week lows.
On Tuesday, 838 companies hit new 52-week lows.
On Wednesday, 340 stocks hit new 52-week lows.
On Monday, 429 stocks made new 52-week lows.
On Tuesday, 400 companies set new 52-week lows.
On Thursday, 529 companies set new 52-week lows.
Gainers Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining